Recently immunotherapies and immune checkpoint blockade of the interactions between programmed cell death protein 1 (PD-1) and its tissue ligand (PD-L1), using monoclonal antibodies, has shown significant and durable benefits compared to standard therapy in NSCLC [4,5]. Here, CD274 is linked to non-small cell lung carcinoma.